Kunal Ramtri brings over two decades of leadership experience across commodity trading, refining, and large-scale business ...

Pyxis Oncology has concluded its first multi-target sublicensing agreement under the new arrangement with a stealth ADC company. This expansion builds on the former agreement, which provided Pyxis ...

Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs ...

Maroussi, Greece – April 24, 2026 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), an international shipping company, announced today that its Chief Financial Officer, Henry Williams, will be stepping ...

Pyxis Oncology needs to pave a longer cash runway. To do so, the Pfizer-partnered antibody-drug conjugate (ADC) biotech is cutting 40% of staff, slimming its programs and looking to monetize royalty ...

Lara Sullivan, Pyxis Oncology CEO, joins Yahoo Finance to discuss the biotech company going public and its oncology treatments for patients with difficult-to-treat cancer. JARED BLIKRE: Well, an IPO ...

Pyxis Oncology (NASDAQ:PYXS) is down ~38% in after-hours trading Wednesday after posting preliminary phase 1 data on PYX-201, an antibody-drug conjugate for solid tumors. The data presented was in six ...